Abstract
There is initial evidence, at least in cardiac surgery, that total intra-venous anesthesia (usually a propofol-based total intravenous anesthesia) is associated with an increased mortality when compared to an anesthetic plan including a halogenated anesthetics. The cardiac protective properties of halogenated agents (desflurane, isoflurane and sevoflurane) have not been confirmed in non-cardiac surgery and mixed results exist for patients admitted in postoperative intensive care units. This article summarizes the papers with the most impressive findings in favor of halogenated anesthetics, but it recognizes that, at the same time, there is no evidence based medicine against the use of propofol, highlighting the need for large randomized trials that should focus on survival.
Keywords: Anesthesia, cardiac surgery, mortality, propofol, halogenated agents, desflurane, isoflurane, sevoflurane.
Current Pharmaceutical Design
Title:Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?
Volume: 20 Issue: 34
Author(s): Giovanni Landoni, Laura Pasin, Giovanni Borghi and Alberto Zangrillo
Affiliation:
Keywords: Anesthesia, cardiac surgery, mortality, propofol, halogenated agents, desflurane, isoflurane, sevoflurane.
Abstract: There is initial evidence, at least in cardiac surgery, that total intra-venous anesthesia (usually a propofol-based total intravenous anesthesia) is associated with an increased mortality when compared to an anesthetic plan including a halogenated anesthetics. The cardiac protective properties of halogenated agents (desflurane, isoflurane and sevoflurane) have not been confirmed in non-cardiac surgery and mixed results exist for patients admitted in postoperative intensive care units. This article summarizes the papers with the most impressive findings in favor of halogenated anesthetics, but it recognizes that, at the same time, there is no evidence based medicine against the use of propofol, highlighting the need for large randomized trials that should focus on survival.
Export Options
About this article
Cite this article as:
Landoni Giovanni, Pasin Laura, Borghi Giovanni and Zangrillo Alberto, Is Time to Change to Halogenated Drugs in Cardiac Surgery, What do we have to do with Propofol?, Current Pharmaceutical Design 2014; 20 (34) . https://dx.doi.org/10.2174/1570161112666140123105536
DOI https://dx.doi.org/10.2174/1570161112666140123105536 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Strategies for Integral Metabolism Profile of Multiple Compounds in Herbal Medicines: Pharmacokinetics, Metabolites Characterization and Metabolic Interactions
Current Drug Metabolism Headspace Analyses in Valuable and Functional Foods: Application of SPME in the Quality Control and Characterization of Olive Oils
Current Analytical Chemistry Muscarinic Acetylcholine Receptor-Interacting Proteins (mAChRIPs): Targeting the Receptorsome
Current Drug Targets Cerebral White Matter Lesions, Risk of Stroke and Cerebrovascular Protection with Angiotensin Receptor Blockers
Current Drug Therapy Current and Experimental Antibody-Based Therapeutics: Insights, Breakthroughs, Setbacks and Future Directions
Current Molecular Medicine Acute Kidney Injury in Pediatric Heart Failure
Current Cardiology Reviews Coffee: A Selected Overview of Beneficial or Harmful Effects on the Cardiovascular System?
Current Vascular Pharmacology New Approaches in the Diagnosis of Atherosclerosis and Treatment of Cardiovascular Disease
Recent Patents on Cardiovascular Drug Discovery The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Thrombin-Activatable Fibrinolysis Inhibitor
Current Medicinal Chemistry A Review of QSAR studies to Discover New Drug-like Compounds Actives Against Leishmaniasis and Trypanosomiasis
Current Topics in Medicinal Chemistry The Na+/H+ Exchanger: A Target for Cardiac Therapeutic Intervention
Current Drug Targets - Cardiovascular & Hematological Disorders Chalcones as Versatile Synthons for the Synthesis of 5- and 6-membered Nitrogen Heterocycles
Current Organic Chemistry Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Triiodothyronine (T3) Effects on Cardiovascular System in Patients with Heart Failure
Recent Patents on Cardiovascular Drug Discovery Plasma-Activated Solutions for Bacteria and Biofilm Inactivation
Current Bioactive Compounds Roles of IL-6-gp130 Signaling in Vascular Inflammation
Current Cardiology Reviews Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Impact of Cardiovascular Factors on Pulse Wave Velocity and Total Vascular Resistance in Different Age Group Patients with Cardiovascular Disorders
Current Aging Science